India Needs to Step Up as a Strategic Innovator in the Global Supply Chain

In a freewheeling conversation, Hari Kiran Chereddi, MD & CEO of HRV Global Life Sciences & New Horizon Global Pharma, explains to Viveka Roychowdhury that "compliance is a currency" and therefore the future of pharma supply chains is a "distributed orchestration, rather than centralised ownership."

HRV Global Life Sciences, under Chereddi's leadership, specialises in virtual Active Pharmaceutical Ingredient (API) manufacturing, posing the question: is it like a super CDMO, which contracts out manufacturing to mid-sized pharma companies in India and then meets the sourcing requirements of global MNC pharma?

Chereddi believes India needs to transform its typical pharma manufacturing. "I do not want to put ourselves in a box of saying we're a CDMO or a CMO or all those terms that are out there today. We're basically reimagining the whole ecosystem."

He emphasizes the importance of compliance and regulatory journey, noting, "India has been an issue. So when you sponsor their quality benchmarks and GMPs to the companies that you're selling to, which markets, how do you do that and what kind of safeguards are there?"

Source: Express Pharma